Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by poor control of voluntary movement, impairment of smooth movement functions and non-movement autonomic dysfunction like orthostatic hypotension. MSA affects the nerve cells that control movement and other body functions like blood pressure and heart rate. Current treatment options for MSA are limited, with no cure available. MSA symptoms are treated to improve function and quality of life.
Multiple System Atrophy Market is estimated to be valued at US$ 137.3 Mn in 2024 and is expected to exhibit a CAGR of 4.4% over the forecast period 2024-2031.
Key Takeaways:
Key players operating in the Multiple System Atrophy (MSA) market are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc. and Among Others. Many players are focusing on developing treatments for MSA to address the significant unmet medical need. For instance, Chelsea Therapeutics developed Northera as an approved treatment for symptomatic neurogenic orthostatic hypotension but discontinued its development as a treatment for MSA.
The rising prevalence of MSA globally is expected to drive market growth significantly. MSA affects around 5 people per 100,000. Increasing awareness about early diagnosis and availability of advanced diagnostic techniques are also supporting early identification of MSA cases.
Technological advancements are also expected to boost the MSA market. Companies are exploring new mechanisms and biomarkers to develop disease-modifying therapies. Biomarkers like alpha-synuclein are being evaluated to identify patients early and monitor treatment responses objectively. Imaging techniques like positron emission tomography (PET) are also helping diagnose MSA and track disease progression non-invasively.
Market Trends:
- Significant focus on early diagnosis: Early and accurate diagnosis helps initiate supportive care and rehabilitation which can significantly improve the quality of life. Companies are collaborating to develop and validate clinical criteria and biomarkers for early detection of MSA.
- Emergence of combination therapies: Since MSA is a complex disease, companies are exploring combination therapies targeting multiple pathogenic processes to achieve synergistic effects. Combination of symptomatic and disease-modifying agents holds promise.
Market Opportunities:
- Emerging Asian markets: Asia-Pacific region, especially China and India, offers lucrative opportunities owing to rising healthcare expenditure and patient population. Partnerships with regional players can boost product access.
- Government support for orphan drugs: Regulatory agencies provide incentives like market exclusivity, research grants, tax credits etc. for orphan drug development. Companies can leverage such opportunities in the MSA market.
Impact Of COVID-19 On Multiple System Atrophy (MSA) Market Growth
The COVID-19 pandemic significantly impacted the growth of the Multiple System Atrophy (MSA) market. Due to lockdowns imposed globally to curb the spread of the virus, there were disruptions in production and supply chain activities. Research and development activities also suffered as social distancing norms were implemented. Many clinical trials were halted temporarily. However, online consultations and telemedicine emerged as important mediums to provide care to MSA patients during this period. Post COVID-19, vaccine developments are expected to help revive the market. But concerns around new variants may continue to pose challenges. Adoption of advanced technologies and innovations focused on early diagnosis and effective treatment will be crucial for driving future growth.
North America Dominates The MSA Market In Terms Of Value
North America currently dominates the global MSA market and holds the largest share in terms of value. This is attributed to factors such as growing prevalence of MSA, rising healthcare expenditure, presence of major players, and availability of advanced treatment options in the region. The US accounts for the major market share in North America. Increasing awareness and government initiatives to support research for rare diseases are also fueling market growth.
Asia Pacific Emerging As The Fastest Growing Region
The Asia Pacific region is emerging as the fastest growing market for MSA globally. This growth can be attributed to rising healthcare infrastructure, growing disposable incomes, increasing focus on rare and orphan diseases, and expanding patient pool in the region. Countries such as China, Japan and South Korea are predicted to offer lucrative opportunities owing to improving standards of diagnosis and management of MSA. Initiatives by market players to penetrate untapped markets also present opportunities for sustained growth prospects.
Get more insights on this topic: https://www.pressreleasebulletin.com/multiple-system-atrophy-msa-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-biomarker-development/
Author Bio
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
What Are The Key Data Covered In This Multiple System Atrophy (MSA) Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Multiple System Atrophy (MSA) 's growth between 2024 and 2031.
:- Accurate calculation of the size of the Multiple System Atrophy (MSA) and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Multiple System Atrophy (MSA) Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Multiple System Atrophy (MSA) vendors
FAQ’s
Q.1 What are the main factors influencing the Multiple System Atrophy (MSA) ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Multiple System Atrophy (MSA) companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Multiple System Atrophy (MSA) ’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment